clinical trial · NCT07217860
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
Bipolar DepressionBipolar I DisorderBipolar DisorderBipolar II DisorderAzetukalner
brief summary
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.
started
Oct 30, 2025
primary completion
Jun 1, 2029
completion
Aug 1, 2029
last updated
Jun 3, 2026
official title
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol